Advertisement

Immune Enhancement Therapy

  • Vladimir V. Klimov
Chapter

Abstract

The reader can find the information on medications used for the immune enhancement therapy for immunocompromised conditions, which take place in the pathology of a wide array of involved organs and tissues of the human body and must be a useful tool for practitioners. It should be noted this critical topic is very rare in immunology manuals.

Supplementary material

466144_1_En_9_MOESM1_ESM.mp3 (6.4 mb)
Audio 9.1 (MP3 6539 kb)

Bibliography

Reviews

  1. JTK H, GCF C, JCB L. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol. 2015;16(21):1–6.  https://doi.org/10.1186/s12865-015-0083-2.CrossRefGoogle Scholar
  2. Mitrevski M, Marrapodi R, Camponeschi A, Cavaliere FM, Lazzeri C, Todi L, Visentini M. Intravenous immunoglobulin and immunomodulation of B-cell – in vitro and in vivo effects. Front Immunol. 2015;6(4):1–5.  https://doi.org/10.3389/fimmu.2015.00004.CrossRefGoogle Scholar
  3. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev. 2001;14(2):430–45.  https://doi.org/10.1128/CMR.14.2.430–445.2001.CrossRefPubMedPubMedCentralGoogle Scholar

Landmark Papers

  1. Li C, Bo L, Liu Q, Jin F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis. 2015;33:90–6.  https://doi.org/10.1016/j.ijid.2014.12.032.CrossRefPubMedGoogle Scholar
  2. Villa E, Garelli V, Braido F, Melioli G, Canonica GW. May we strengthen the human natural defenses with bacterial lysates? World Allergy Organ J. 2010;3(2):17–23.Google Scholar

Suggested Reading

  1. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879–85.CrossRefGoogle Scholar
  2. Andreone P, Cursaro C, Gramenzi A, et al. In vitro effect of thymosin-a1 and interferon-a on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat. 2001;8:194–201.CrossRefGoogle Scholar
  3. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938–56.  https://doi.org/10.1080/10408398.2011.619671.CrossRefPubMedGoogle Scholar
  4. Durmont F, de Villemeur M. Implementing immunostimulants. Eur Biopharm Rev. 2011;12(155):2988.Google Scholar
  5. Kedl JD, Kedl RM. How squalene GLAdly helps generate antigen-specific T cells via antigen-carrying neutrophils and IL-18. Eur J Immunol. 2015;45(2):376–9.  https://doi.org/10.1002/eji.201445379.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus Res. 2015;209:11–22.  https://doi.org/10.1016/j.virusres.2015.02.003.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M. The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol. 2012;12:728–34.  https://doi.org/10.1038/nri3312.CrossRefPubMedGoogle Scholar
  8. Kotredes KP, Thomas B, Gamero AM. The protective role of type I interferon in the gastrointestinal tract. Front Immunol. 2017;8(410):1–24.  https://doi.org/10.3389/fimmu.2017.00410.CrossRefGoogle Scholar
  9. Li C-L, Zhang T, Saibara T, Nemoto Y, Ono M, Akisawa N, Iwasaki S, Maeda T, Onishi S. Thymosin a1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int Immunopharmacol. 2002;2:39–46.CrossRefGoogle Scholar
  10. Lucas RM, Gorman S, Geldenhuys S, Hart PH. Vitamin D and immunity. F1000Prime Rep. 2014;6(118):1–11.  https://doi.org/10.12703/P6-118.CrossRefGoogle Scholar
  11. Monroe KM, McWhirter SM, Vance RE. Induction of type I interferons by bacteria. Cell Microbiol. 2010;12(7):881–90.  https://doi.org/10.1111/j.1462-5822.2010.01478.x.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Ningrum RA. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica. 2014;970(315):1–8.  https://doi.org/10.1155/2014/970315.CrossRefGoogle Scholar
  13. Peter JG, Heckmann JM, Novitzky N. Recommendations for the use of immunoglobulin therapy for immunomodulation and antibody replacement. S Afr Med J. 2014;104(11):796–805.  https://doi.org/10.7196/SAMJ.8965.CrossRefGoogle Scholar
  14. Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS. 2015;123(4):275–88.  https://doi.org/10.1111/apm.12351.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Seton-Rogers S. Immunotherapy: powerful combinations. Nat Rev Cancer. 2016;16:757–69.  https://doi.org/10.1038/nrc.2016.136.CrossRefPubMedGoogle Scholar
  16. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharm Des. 2009;15(11):1238–47.CrossRefGoogle Scholar
  17. Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. 2011;2(CD003993)  https://doi.org/10.1002/14651858.CD003993.pub3.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Vladimir V. Klimov
    • 1
  1. 1.Clinical Immunology and Allergy DepartmentSiberian State Medical UniversityTomskRussia

Personalised recommendations